NasdaqGM:PRCTMedical Equipment
How Investors Are Reacting To PROCEPT BioRobotics (PRCT) UBS Coverage Initiation And 2027 Profitability Outlook
On 12 December 2025, UBS analyst Danielle Antalffy initiated coverage of PROCEPT BioRobotics with a bullish view, highlighting expectations for expanding revenue, improving gross margins, and cost efficiencies that could support profitability by 2027.
This upbeat initiation adds to already optimistic analyst sentiment around PROCEPT’s urology-focused surgical robotics platform, with no Sell ratings and most covering analysts expecting meaningful growth in its Aquablation-based...